Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide in Pediatric Patients With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
NCT03969329Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Dec 2019
- Primary completion
- Jun 2027
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Percent Change From Baseline in iPTH. Started Dec 2019; status: recruiting.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03969329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969329.